0.06
+0(+0.00%)
Currency In USD
| Previous Close | 0.06 |
| Open | 0.06 |
| Day High | 0.06 |
| Day Low | 0.05 |
| 52-Week High | 70 |
| 52-Week Low | 0.05 |
| Volume | 76,750 |
| Average Volume | 2.68M |
| Market Cap | 66,295 |
| PE | -0.01 |
| EPS | -3.68 |
| Moving Average 50 Days | 0.19 |
| Moving Average 200 Days | 7.07 |
| Change | 0 |
If you invested $1000 in CERo Therapeutics Holdings, Inc. (CERO) since IPO date, it would be worth $0 as of January 09, 2026 at a share price of $0.055. Whereas If you bought $1000 worth of CERo Therapeutics Holdings, Inc. (CERO) shares 3 years ago, it would be worth $0 as of January 09, 2026 at a share price of $0.055.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML
GlobeNewswire Inc.
Jan 07, 2026 2:09 PM GMT
Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”), a
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
GlobeNewswire Inc.
Dec 17, 2025 1:00 PM GMT
Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“
CERo Therapeutics Announces Trading on OTCQB Market
GlobeNewswire Inc.
Dec 02, 2025 12:30 PM GMT
Company’s Shares Will Continue to Trade Under Ticker CERO SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB : CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company develo